Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts.
Company Background and Technology Edge
Founded in 2017, Meiitech boasts an in-house developed gene sequencing instrument and supporting reagents that offer ultra-long read lengths, no amplification, quickness, accuracy, and low cost. These features position Meiitech at the forefront of early cancer detection technology, leveraging nanopore sequencing to provide advanced diagnostic solutions.
Investor Impact and Future Prospects
The investment by Autobio Diagnostics, a prominent player in the diagnostics industry, underscores the potential of Meiitech’s technology in revolutionizing cancer detection. With this funding, Meiitech is poised to enhance its product offerings and expand its reach in the global cancer diagnostics market.-Fineline Info & Tech
